Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | VSIR | Q9H7M9 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7547685 | 0.89 | ACHE (0.56) | CCR2MAP4K4DPP7HSP90AA1HSP90AB1 | |
| SCHEMBL7553583 | 0.89 | MAP4K4 (0.48) | CCR2MAP4K4DPP7HSP90AA1HSP90AB1 | |
| SCHEMBL7553785 | 0.89 | CCR2 (0.62) | CCR2DPP7HDAC6ACHEPARP1 | |
| SCHEMBL7549696 | 0.87 | ACHE (0.53) | MAP4K4DPP7HDAC6ACHEATR | |
| SCHEMBL7554505 | 0.83 | MAP4K4 (0.48) | MAP4K4DPP7HDAC6ACHEATR | |
| SCHEMBL7549558 | 0.83 | MAP4K4 (0.48) | MAP4K4DPP7HDAC6ACHEATR | |
| SCHEMBL7546612 | 0.82 | CCR2 (0.51) | CCR2DPP7ACHERHEBSIGMAR1 | |
| SCHEMBL7547110 | 0.81 | CCR2 (0.53) | CCR2MAP4K4DPP7HDAC6ACHE | |
| SCHEMBL7554493 | 0.81 | MAP4K4 (0.52) | MAP4K4DPP7HSP90AA1HSP90AB1HDAC6 | |
| SCHEMBL7554554 | 0.80 | MAP4K4 (0.48) | MAP4K4DPP7ATRPARP1VSIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | CCR2 2/4885MAP4K4 1964/4885DPP7 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.